Class Action Lawsuit Filed Against Iovance Biotherapeutics: Important Investor Information

Overview

A new class action lawsuit has been initiated against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), as announced by Levi & Korsinsky, LLP. This action aims to support investors who may have experienced financial losses due to alleged securities fraud between May 9, 2024, and May 8, 2025. If you are an investor in Iovance, it is crucial to be aware of the details surrounding this case as the deadline for joining the action is July 14, 2025.

Case Background

The lawsuit centers on claims that Iovance Biotherapeutics misled investors about its true growth potential. Throughout the defined class period, the company allegedly made overly optimistic statements while failing to disclose critical adverse information. According to the complaint, Iovance failed to effectively capitalize on demand for its treatments due to inadequate capacity and operational challenges.

A particularly noteworthy event occurred on July 25, 2024, when Iovance announced its second-quarter financial results for fiscal 2024. Following this report, which included a significant reduction in revenue guidance for the entire fiscal year, the company's stock saw a dramatic drop. Iovance disclosed that maintenance schedules and lower-than-expected sales resulted in diminished financial performance. After revealing this information, the stock plummeted, closing at $1.75 per share on May 9, 2025, representing a substantial decline of approximately 44.8% in just one day.

Who Can Participate?

If you have suffered financial losses due to your investments in Iovance during the specified time frame, you may qualify to participate in the class action lawsuit. You have until July 14, 2025, to request the Court appoint you as the lead plaintiff. However, it is important to note that participating does not require you to be a lead plaintiff to receive compensation from any potential recovery.

No Fees Involved

For individuals considering joining the lawsuit, there is no financial risk involved. Class members may be eligible for compensation without incurring out-of-pocket expenses or fees. This no-cost participation ensures that all investors can seek justice without financial barriers.

Legal Expertise from Levi & Korsinsky

Levi & Korsinsky has a strong history of advocating for investors’ rights and recovering significant amounts for affected shareholders, having achieved hundreds of millions of dollars in settlements over the past two decades. The firm boasts a team of over 70 professionals and continues to be recognized as one of the top securities litigation firms in the United States, consistently ranking in the ISS Securities Class Action Services’ Top 50 Report.

Next Steps

If you are an investor in Iovance who endured losses during the class action period, it is imperative for you to act soon. To participate or to receive more detailed information, please contact Levi & Korsinsky directly. Investors can reach out via email or telephone for assistance.

For further inquiries, you may contact:
Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

Conclusion

In conclusion, if you are an affected investor in Iovance Biotherapeutics, now is the time to take action. Ensure your rights are protected and explore the possibility of recovering your losses by joining this important class action lawsuit.